Jiwon Oh, AAN 2022: Tolebrutinib as a potential treatment in relapsing multiple sclerosis – Long-term extension study, phase 2b, 18-month results

Tolebrutinib is an oral, CNS-penetrant Bruton’s tyrosine kinase inhibitor with dual mechanism of action: peripheral B cell modulation and re-establishment of CNS microglial homeostasis. Dr Jiwon Oh (St. Michael’s Hospital, University of Toronto, Canada) joins us to discuss the phase 2b trial (NCT03889639), investigating safety and efficacy of tolebrutinib in patients with relapsing multiple sclerosis.

The abstract entitled ‘Safety and Clinical Efficacy Outcomes From the Long-term Extension Study of Tolebrutinib in Patients With Relapsing Multiple Sclerosis: 18-Month Results’ was presented at the American Academy of Neurology (AAN) annual meeting, April 2-7, 2022.

Questions:

1. What is tolebrutinib and what are its potential advantages over existing therapies in the treatment of patients with relapsing multiple sclerosis (MS)? (0:15)
2. What did the Phase 2 study teach us about the efficacy and safety of tolebrutinib in this indication? (2:37)
3. What will be the next step in the clinical development of tolebrutinib? (4:53)

Disclosures: Jiwon Oh is a consultant and is on the advisory board for Sanofi-Genzyme, and also receives honoraria/honorarium from Sanofi-Genzyme.

Support:  Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of AAN 2022